Clinical trial
Rituximab, Vaccine Therapy, and GM-CSF in Treating Patients With Non-Hodgkin's…
NCT00258336 · Favrille, Industry · Unknown status
Key facts
| NCT number | NCT00258336 |
|---|---|
| Title | Rituximab, Vaccine Therapy, and GM-CSF in Treating Patients With Non-Hodgkin's Lymphoma |
| Official title | Phase II Trial of Maintenance Rituximab Plus FavId® and GM-CSF Immunotherapy in Patients With Treatment-Naive Indolent B-Cell Lymphoma |
| Lead sponsor | Favrille, Industry |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Biological |
| Interventions | autologous immunoglobulin idiotype-KLH conjugate vaccine, rituximab, sargramostim |
| Enrollment | 56 |
| Start date | Aug 1, 2004 |
| Primary completion | Nov 1, 2009 |
| First posted | Nov 24, 2005 |
| Last update posted | Jan 10, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: